

21st June, 2019

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Disclosure of related party transactions for the half year ended 31st March, 2019

Dear Sir/Madam,

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 31st March, 2019.

This disclosure is also being uploaded on the website of the Company i.e. www.cipla.com.

This is for your information and record.

Thanking you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Prepared by: Vivek Vadwana

Information on related party transactions as required by Ind AS-24 - 'Related Party Disclosures' are given below:

List of related parties

A. Associate

Stempeutics Research Private Limited
Avenue Therapeutics Inc. (w.e.f. 8th February, 2019)

B. Key Management Personnel

Ms. Samina Vaziralli – Executive Vice-Chairperson
Mr. Umang Vohra – Managing Director and Global Chief Executive Officer
Mr. S. Radhakrishnan – Whole-time Director (upto 11th November, 2017)
Mr. Kedar Updhave – Global Chief Financial Officer
Dr. Raghunathan Ananthanarayanan - President and Global Chief Operating Officer
(w.e.f. 08th August, 2018)

C. Non-Executive Chairman & Non-Executive Vice Chairman

Dr. Y. K. Hamied, Chairman
Mr. M. K. Hamied, Vice Chairman

D. Non-Executive Directors

Mr. Ashok Sinha
Mr. Adil Zainulbhai
Ms. Punita Lal
Ms. Naina Lal Kidwai
Ms. Ireena Vittal (Upto 31st March, 2019)
Mr. Peter Lankau
Dr. Peter Mugenyi
Mr. S Radhakrishnan (w.e.f 12th November, 2017)

E. Entities over which Key Management Personnel are able to exercise significant influence

Cipla Foundation
Hamied Foundation
Cipla Cancer and AIDS Foundation

F. Trust over which entity has control/significant influence

Cipla Limited Employees Provident Fund
Cipla Limited Employees Gratuity
Cipla Employees Stock Option Trust
Cipla Health Employees Stock Option Trust



Particulars	Rs. in Crore For the half year ended 31 st March, 2019
A. Remuneration (Including sitting fees)*	
Dr. Y.K. Hamied	1.02
Mr. M.K. Hamied	1.03
Ms. Samina Vaziralli	3.50
Mr. Umang Vohra	8.54
Mr. S. Radhakrishnan	1.04
Mr. Kedar Upadhye	1.79
Mr. Ashok Sinha	0.23
Mr. Adil Zainulbhai	0.19
Ms. Punita Lal	0.20
Ms. Naina Lal Kidwai	0.21
Ms. Ireena Vittal	0.20
Mr. Peter Lankau	0.22
Dr. Peter Mugenyi	0.22
Dr. Raghunathan Ananthanarayanan	3.87
	22.26
* Expenses towards gratuity and leave encashment provisions are determined actuarially on an overall company basis at the end of each year and accordingly have not been considered in the above information	
B. Purchase of goods	
Stempeutics Research Private Limited	0.16
	0.16
C. Testing and analysis charges paid	
Stempeutics Research Private Limited	1.59
	1.59
D. Contribution to provident fund and other fund	
Cipla Limited Employees Gratuity Fund	15.00
Cipla Limited Employees Provident Fund	20.84
	35.84
E. Donations given	
Cipla Foundation	18.80
	18.80
F. Rent received	
Dr. Y.K. Hamied (Rs.10,020/-)	0.00
	0.00
G. Reimbursement of operating/other expenses	
Stempeutics Research Private Limited	0.18
	0.18



Particulars

H. Investment made during the period

Avenue Therapeutics Inc.	242.04
	242.04

I. Payable to Key Management Personnel

Dr. Y.K. Hamied	2.00
Mr. M.K. Hamied	2.00
Ms. Samina Vaziralli	2.30
Mr. Umang Vohra	5.50
Mr. S.Radhakrishnan	2.00
Mr. Kedar Upadhye	0.91
Mr. Ashok Sinha	0.40
Mr. Adil Zainulbhai	0.32
Ms. Punita Lal	0.35
Ms. Naina Lal Kidwai	0.35
Ms. Ireena Vittal	0.35
Mr. Peter Lankau	0.40
Dr. Peter Mugenyi	0.40
Dr. Raghunathan Ananthanarayanan	1.78
	19.06

J. Contribution payable to provident fund

Cipla Employees Provident Fund	3.40
	3.40

K. Advances receivable from gratuity fund

Cipla Limited Employees Gratuity Fund	9.51
	9.51

